AJR Am J Roentgenol. 2015 Aug;205(2):259-70. doi: 10.2214/AJR.14.13575.
Perng P1, Marcus C1, Subramaniam RM1,2,3,4.
OBJECTIVE: Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of (18)F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma.
CONCLUSION: FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.